Mepolizumab: First Global Approval

Drugs

Volumn 75, Issue 18, 2015, Pages 2163-2169

  Keating, Gillian M ^a  

^a Springer ^*  (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 5; MEPOLIZUMAB; ANTIASTHMATIC AGENT; MONOCLONAL ANTIBODY;

ALLERGIC REACTION; ASTHMA; CENTRAL VOLUME OF DISTRIBUTION; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG METABOLISM; ELIMINATION HALF-LIFE; EOSINOPHIL COUNT; EOSINOPHILIC GRANULOMA; HEADACHE; HUMAN; HYPEREOSINOPHILIC SYNDROME; INJECTION SITE REACTION; NOSE POLYP; PHARMACODYNAMICS; PHENOTYPE; REVIEW; RHINOPHARYNGITIS; STEADY STATE; UPPER RESPIRATORY TRACT INFECTION; ADULT; ANTAGONISTS AND INHIBITORS; CHILD; DRUG APPROVAL; EOSINOPHILIA; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX;

ADULT; ANTI-ASTHMATIC AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; ASTHMA; CHILD; DRUG APPROVAL; EOSINOPHILIA; HUMANS; INTERLEUKIN-5; SEVERITY OF ILLNESS INDEX;

EID: 84949108027     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-015-0513-8     Document Type: Review

References (32)

1. Smith DA, Minthorn EA, Beerahee M. Pharmacokinetics and pharmacodynamics of mepolizumab, an anti-interleukin-5 monoclonal antibody. Clin Pharmacokinet. 2011;50(4):215-27.
2. Chung KF. Defining phenotypes in asthma: a step towards personalized medicine. Drugs. 2014;74(7):719-28.
3. Walford HH, Doherty TA. Diagnosis and management of eosinophilic asthma: a US perspective. J Asthma Allergy. 2014;7:53-65.
4. Food and Drug Administration. FDA approves Nucala to treat severe asthma. 2015. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm471031.htm. Accessed 6 Nov 2015.
5. European Medicines Agency. Nucala (mepolizumab): summary of opinion. 2015. http://www.ema.europa.eu/docs/en-GB/document-library/Summary-of-opinion-Initial-authorisation/human/003860/WC500194118.pdf. Accessed 13 Oct 2015.
6. GlaxoSmithKline. GSK submits Japan regulatory application for mepolizumab in severe eosinophilic asthma [media release]. 2015. http://www.gsk.com. Accessed 15 Oct 2015.
7. Food and Drug Administration. Search orphan drug designations and approvals. 2015. http://www.accessdata.fda.gov/scripts/opdlisting/oopd/OOPD-Results-2.cfm. Accessed 15 Oct 2015.
8. European Medicines Agency. Public summary of opinion on orphan drug designation: mepolizumab for the treatment of Churg-Strauss syndrome. 2013. http://www.ema.europa.eu/docs/en-GB/document-library/Orphan-designation/2013/04/WC500141553.pdf. Accessed 15 Oct 2015.
9. European Medicines Agency. Public summary of opinion on orphan designation: mepolizumab for the treatment of hypereosinophilic syndrome. 2010. http://www.ema.europa.eu/docs/en-GB/document-library/Orphan-designation/2009/10/WC500006418.pdf. Accessed 15 Oct 2015.
10. GlaxoSmithKline. Regulatory update: mepolizumab for the treatment of hypereosinophilic syndrome (HES) [media release]. 2009. http://www.gsk.com. Accessed 12 Oct 2015.
11. GlaxoSmithKline. Nucala (mepolizumab) for injection, for subcutaneous use. 2015. https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing-Information/Nucala/pdf/NUCALA-PI-PIL.PDF. Accessed 6 Nov 2015.
12. Pouliquen IJ, Kornmann O, Barton SV, et al. Characterization of the relationship between dose and blood eosinophil response following subcutaneous administration of mepolizumab. Int J Clin Pharmacol Ther. 2015;53(12):1015-27.
13. Büttner C, Lun A, Splettstoesser T, et al. Monoclonal anti-interleukin-5 treatment suppresses eosinophil but not T-cell functions. Eur Respir J. 2003;21(5):799-803.
14. Leckie MJ, ten Brinke A, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet. 2000;356(9248):2144-8.
15. Flood-Page P, Swenson C, Faiferman I, et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med. 2007;176(11):1062-71.
16. Flood-Page PT, Menzies-Gow AN, Kay AB, et al. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med. 2003;167(2):199-204.
17. Stein ML, Villanueva JM, Buckmeier BK, et al. Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels. J Allergy Clin Immunol. 2008;121(6):1473-83, 83.e1-4.
18. Garrett JK, Jameson SC, Thomson B, et al. Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. J Allergy Clin Immunol. 2004;113(1):115-9.
19. Flood-Page P, Menzies-Gow A, Phipps S, et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest. 2003;112(7):1029-36.
20. Menzies-Gow A, Flood-Page P, Sehmi R, et al. Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics. J Allergy Clin Immunol. 2003;111(4):714-9.
21. Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009;360(10):973-84.
22. Nair P, Pizzichini MM, Kjarsgaard M, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med. 2009;360(10):985-93.
23. Haldar P, Brightling CE, Singapuri A, et al. Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis. J Allergy Clin Immunol. 2014;133(3):921-3.
24. Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):651-9.
25. Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198-207.
26. Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371(13):1189-97.
27. Rothenberg ME, Klion AD, Roufosse FE, et al. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med. 2008;358(12):1215-28.
28. Roufosse F, de Lavareille A, Schandene L, et al. Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome. J Allergy Clin Immunol. 2010;126(4):828-35.e3.
29. Roufosse FE, Kahn J-E, Gleich GJ, et al. Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes. J Allergy Clin Immunol. 2013;131(2):461-7.e1-5.
30. Duncan EA, Ortega H, Gleich G, et al. Observational experience describing the use of mepolizumab in paents with hpereosinophilic syndrome [abstract no. 257]. Am J Respir Crit Care Med. 2015;191:A1365.
31. Kim S, Marigowda G, Oren E, et al. Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome. J Allergy Clin Immunol. 2010;125(6):1336-43.
32. Gevaert P, Van Bruaene N, Cattaert T, et al. Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. J Allergy Clin Immunol. 2011;128(5):989-95.e1-8.